Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit additional patients. The company expects to present the preliminary data from this cohort at a scientific meeting this year. The study is expected to recruit up to 150 patients.
- Recruitment in cohort 3 is ongoing, evaluating lacutamab as monotherapy in KIR3DL2 non-expressing mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma.
- The company also plans to initiate two parallel trials to evaluate lacutamab in KIR3DL2-expressing patients with relapsed/refractory peripheral T-cell lymphoma, including a Company-sponsored Phase 1b trial to evaluate lacutamab as monotherapy in KIR3DL2-expressing patients with relapsed PTCL, and an investigator-sponsored trial to evaluate lacutamab in combination with chemotherapy GEMOX, versus GEMOX alone in KIR3DL2-expressing relapsed/refractory patients.
- Webcast and conference call is scheduled for 8:00 a.m. ET today.
- Price Action: IPHA shares closed 5.5% higher at $4.63 on Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!